Nucleic Acid Vector Tablets via Lipid Complex Drying
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of nucleic acid vectors as colloidal suspensions face constraints such as limited vector size and the need for sterile preparations, making them challenging for development as new drug candidates.
Innovation Solution
A process for manufacturing tablets comprising a complex of nucleic acids and lipid particles with cationic lipids, specifically liposomes or micelles, which involves drying, mixing with compression excipients, and compressing to form stable tablets suitable for oral or transmucosal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If nucleic acid vectors are formulated as colloidal suspensions for parenteral administration, then the vectors can be transported into patient's cells, but the formulation imposes constraints such as limited vector size and the need for sterile preparations
Solution Approach 1:
The patent changes the physical state parameter from liquid colloidal suspension to solid tablet form. This parameter change eliminates the need for sterile preparation constraints and allows greater flexibility in vector size while maintaining biological activity through controlled release mechanisms.
Solution Approach 2:
The patent introduces an intermediary release mechanism where the tablet matrix controls the delivery of nucleic acid vectors to cells. This intermediary system allows the vectors to be released in a controlled manner, overcoming the limitations of direct parenteral administration while maintaining cell penetration capability.
2Ease of manufacture
If nucleic acid vectors are administered as colloidal suspensions, then they can be injected directly into cells, but the formulation requires sterile preparations which complicates the development process
Solution Approach 1:
The patent employs a disposable tablet formulation that does not require sterile preparation. The tablet can be manufactured aseptically and stored stably, eliminating the time-consuming sterile preparation steps while maintaining the therapeutic effect through controlled release of the nucleic acid vectors.
Solution Approach 2:
The patent performs preliminary action by pre-formulating the nucleic acid vectors into stable tablet matrices before administration. This preliminary formulation eliminates the need for sterile preparation at the time of administration, significantly reducing development time while maintaining vector efficacy.
3Reliability
If the aqueous mixture is dried to form a tablet, then the biological activity of nucleic acid vectors is maintained, but the drying process requires specific excipients and conditions
Solution Approach 1:
The patent changes the physical state from aqueous suspension to dry powder through controlled drying. By optimizing drying parameters and selecting appropriate excipients, the process maintains biological activity while achieving a stable solid form suitable for tablet compression and long-term storage.
Solution Approach 2:
The patent uses composite materials by combining nucleic acid vectors with specific excipients during the drying process. This composite formulation maintains biological activity while simplifying the overall process through the use of well-established excipient systems that facilitate drying and tablet formation.
4Ease of manufacture
If compression excipients are mixed with the dry mixture, then the tablet can be formed, but the compression process must preserve the biological activity of the nucleic acid complex
Solution Approach 1:
The patent optimizes compression parameters such as pressure, temperature, and time to form the tablet while preserving biological activity. By controlling these parameters, the process achieves successful tablet formation without denaturing the nucleic acid vectors or compromising their therapeutic effect.
Solution Approach 2:
The patent incorporates protective excipients and formulation strategies before compression to cushion and protect the nucleic acid vectors from mechanical damage. This beforehand protection ensures that the compression process forms the tablet while maintaining the biological activity and structural integrity of the nucleic acid complex.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tablet formulation maintains the biological activity of nucleic acid vectors, allows for controlled release, and overcomes the constraints of traditional suspensions, enhancing patient comfort and treatment compliance.
Implementation Method 1
a complex between (i) a nucleic acid; and (ii) a lipid particle comprising a cationic lipid
Implementation Method 2
drying, in particular by freeze-drying, an aqueous mixture
Data Source
AI summary
The invention relates to a process for the manufacture of a tablet comprising a nucleic acid vector.